Zheng Liu ENT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

1 in Phase 3

Quick facts

Phase 3 pipeline

Mometasone furoate as a nasal spray · Otolaryngology / Allergy
Mometasone furoate is a corticosteroid that reduces inflammation in the nasal passages by suppressing immune and inflammatory responses.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Zheng Liu ENT portfolio CI brief
Zheng Liu ENT pipeline updates RSS

Frequently asked questions about Zheng Liu ENT

What is Zheng Liu ENT's pipeline?

Zheng Liu ENT has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Mometasone furoate as a nasal spray.

Sector hub: All tracked pharma companies